Abeona Therapeutics Announces Option Exercise By Beacon Therapeutics For Novel AAV204 Capsid For Ophthalmology Gene Therapy
July 1 (Reuters) - Abeona Therapeutics Inc ABEO.O:
ABEONA THERAPEUTICS® ANNOUNCES OPTION EXERCISE BY BEACON THERAPEUTICS FOR NOVEL AAV204 CAPSID FOR OPHTHALMOLOGY GENE THERAPY
ABEONA THERAPEUTICS INC - TO RECEIVE UNDISCLOSED UPFRONT PAYMENT AND TIERED ROYALTIES
ABEONA THERAPEUTICS INC - WORLDWIDE NON-EXCLUSIVE LICENSE AGREEMENT BETWEEN ABEONA AND BEACON
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Big Tech’s AI Data Center Power Demands Trigger $15B PJM Auction and a Nuclear SMR Boom

Tradingkey








